We recently recorded a conversation with Dr Antoine Iannessi, Head of Medical Affairs at Median Technologies. Hosted by Connor Anderson, U.S. Project Manager II at Median Technologies, the discussion was about how variability in imaging interpretation can lead to discrepancies in oncology clinical trial results. Additionally, they talk about ways to address and overcome the discrepancies. 

This is an excerpt from our podcast “Shaping Results through Imaging: Addressing Variability in Oncology Trials”.  

Listen to full version of the podcast here :

Connor Anderson – Project Manager II, Median Technologies: Thank you for joining this podcast. We are going to start the interview by setting the stage. Can you describe the role imaging variability plays in oncology drug trials and how it can impact trial results? 

Dr. Antoine Iannessi, Head of Medical Affairs, Median Technologies: Currently, imaging plays a crucial role in assessing the efficacy of oncology drugs. Simply put, imaging  allows us to visualize tumor size, progression, and response to the treatment. And this is done by repeating imaging evaluation. When we repeat those imaging assessments, the variability can introduce uncertainty into trial outcomes. And there can be an inconsistency in three primary areas:  
• The first one is the acquisition of image.  
• The second one would be the interpretation of those images by the radiologist. 
• Finally, the analysis can lead to misclassification of the treatment responses. This potentially affects the overall assessment of the drug efficacy.  

Variability also has impacts on the trial statistical power. And it makes challenging to actually accurately determine whether a drug is effective or not. If the imaging assessment are too much variable.  

So that’s the reason why clinical trial imaging services (such as Median’s iCRO business) play a vital role in managing and controlling variability during the clinical trial process. Their expertise in medical imaging as well as in regulatory compliance and quality control  enable them to implement measures that will minimize the various sources of variability. And they organize blinded centralized imaging review by independent experts. This is also one way we can actually supervise and monitor the variability during the imaging assessment. 

Read our scientific publication on double read variability in lung trials 

Connor Anderson: Wonderful, I heard there are various sources of variability . Can you  elaborate on each of those? 

Dr. Antoine Iannessi: Sure. As a Head of Medical Affairs, I oversee the evaluation conducted by those independent radiologists […] 

Antoine Iannessi
Head of Medical Affairs – Median Technologies

Connor Anderson
Project Manager II, US – Median Technologies

Want to know more about Median’s AI-powered imaging services for oncology trials? Click here!

You can also read


Explore 5 Transformative Ways AI-Powered Imaging Can Positively Impact Oncology Clinical Trials


Delivering best-in-class imaging services and expertise to clinical sponsors worldwide


Closing the Gap: Strategies for Resolving Imaging Discrepancies in Oncology Drug Trials